Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sevoflurane
Drug ID BADD_D02015
Description Sevoflurane, also called fluoromethyl, is an ether inhalation anaesthetic agent used for the induction and maintenance of general anesthesia. It is a volatile, non-flammable, non-irritant, and easy-to-administer compound with a low solubility profile and blood-to-gas partition coefficient.
Indications and Usage Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
Marketing Status Prescription
ATC Code N01AB08
DrugBank ID DB01236
KEGG ID D00547
MeSH ID D000077149
PubChem ID 5206
TTD Drug ID D0W6ZF
NDC Product Code 0074-4456; 10019-651; 0781-6160; 12164-005; 66794-015; 66794-022; 54122-4486; 10019-653; 42677-110; 66794-012; 57884-0036; 12164-009
Synonyms Sevoflurane | Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl Ether | Fluoromethyl Hexafluoroisopropyl Ether | Sevorane | Ultane | BAX 3084
Chemical Information
Molecular Formula C4H3F7O
CAS Registry Number 28523-86-6
SMILES C(OC(C(F)(F)F)C(F)(F)F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cognitive disorderApoptosis regulator Bcl-2P10415T3130925774088
Cognitive disorderCaspase-3P42574T5794325774088
Cognitive disorderGlycine receptor subunit alpha-1P23415T5026925774088
Cognitive disorderApoptosis regulator BAXQ07812T8925125774088
Nerve injuryCaspase-3P42574T5794325774088
Nerve injuryApoptosis regulator BAXQ07812T8925125774088
Nerve injuryGlycine receptor subunit alpha-1P23415T5026925774088
Nerve injuryApoptosis regulator Bcl-2P49950Not Available25774088
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle twitching15.05.03.005--Not Available
Myocardial infarction24.04.04.009; 02.02.02.0070.000617%
Myoclonus17.02.05.0080.000788%Not Available
Nausea07.01.07.001--
Nephrogenic diabetes insipidus20.05.03.010; 14.05.07.0020.000788%Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oliguria20.01.03.004--Not Available
Oxygen saturation decreased13.02.01.0040.002364%Not Available
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Polydactyly15.11.07.010; 03.11.07.0100.000206%Not Available
Premature baby18.04.02.0010.000788%Not Available
Pruritus23.03.12.001--
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.001182%Not Available
Pulmonary oedema02.05.02.003; 22.01.03.0030.001970%
Pyrexia08.05.02.0030.003153%
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Respiratory depression17.02.05.047; 22.02.01.0100.001182%Not Available
Respiratory distress22.02.01.0120.001182%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000514%
Rhabdomyolysis15.05.05.0020.001970%
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.0010.005911%
Septic shock24.06.02.011; 11.01.11.0040.000720%Not Available
Shock24.06.02.002--Not Available
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages